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ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is now the commonest cause of liver disease in devel-
oped countries affecting 25–33% of the general population and up to 75% of those with obesity.
Recent data suggest that alterations in DNA methylation may be related to NAFLD pathogenesis
and progression and we have previously shown that dynamic changes in the cell lineage identifier
5-hydroxymethylcytosine (5hmC) may be important in the pathogenesis of liver disease. We used
a model of diet-induced obesity, maintaining male mice on a high-fat diet (HFD) to generate
hepatic steatosis. We profiled hepatic gene expression, global and locus-specific 5hmC and
additionally investigated the effects of weight loss on the phenotype. HFD led to increased
weight gain, fasting hyperglycaemia, glucose intolerance, insulin resistance and hepatic periportal
macrovesicular steatosis. Diet-induced hepatic steatosis associated with reversible 5hmC changes
at a discrete number of functionally important genes. We propose that 5hmC profiles are a useful
signature of gene transcription and a marker of cell state in NAFLD and suggest that 5hmC
profiles hold potential as a biomarker of abnormal liver physiology.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is now
the commonest cause of liver disease in developed
countries, affecting 25–33% of the general popula-
tion and up to 75% of those with obesity [1–4].
NAFLD is strongly associated with obesity, insulin
resistance, type 2 diabetes and cardiovascular disease
[1,2], and the increasing prevalence of these disor-
ders places a substantial burden on public health
resources. Indeed, NAFLD is an early predictor of,
and important determinant for, the development of
type 2 diabetes and the metabolic syndrome [5].
NAFLD encompasses a spectrum of liver disease
and whilst simple steatosis, involving hepatic lipid
accumulation without inflammation or hepatocellu-
lar damage, is considered relatively benign, it can
progress to non-alcoholic steatohepatitis (NASH),
fibrosis and cirrhosis, and up to 27% of those with
cirrhosis will develop hepatocellular carcinoma
(HCC) [6,7]. The inter-individual variability in the
risk of progression, coupled with a lack of under-
standing of underlying mechanisms has limited the
development of effective biomarkers of risk and
therapeutic interventions.
Recent data using both genome-wide and candi-
date gene analysis in human liver biopsy specimens
have identified alterations in DNA methylation
(5-methylcytosine, 5mC) over promoter and genic
regions of functionally relevant genes and pathways
in association with disease state, suggesting that epi-
genetic dysregulationmay play a role in the pathogen-
esis and progression of NAFLD [8–10]. Further
evidence comes from rodent studies showing that
methyl donor restriction causes NAFLD-like liver
injury [11] whilst supplementation protects against
diet-induced hepatic steatosis [12]. DNA methylation
(5-methylcytosine, 5mC) is important in the regula-
tion of gene expression, and 5mC tends to be found
over heterochromatic and repetitive portions of the
genome. In contrast, 5-hydroxymethylcytosine
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(5hmC) is enriched over the bodies of expressed genes
and regulatory enhancer elements, with differential
enrichment across promoters in many tissues [13–
17]. In adult liver, 5hmC is overrepresented in genes
involved in active catabolic and metabolic processes
[16]. Although 5hmC functions in DNA demethyla-
tion pathways, catalysed by the Ten-Eleven-
Translocation enzymes (Tets) [18], it may also act as
a functional DNA methylation mark [19].
Importantly, our appreciation of 5hmC patterns in
disease is limited, since widely used bisulphite sequen-
cing methods do not discriminate 5mC and 5hmC
[20,21]. We have recently shown that ‘environmental’
insults can drive dynamic, reciprocal changes in 5mC/
5hmC, suggesting that 5hmC profiles may be a useful
dynamic signature of hepatic gene transcription and
a marker of cell state [22]. For example, exposure to
the non-genotoxic hepatic carcinogen phenobarbital
results in altered 5mC and 5hmC profiles with
a switch from a repressive to an active chromatin
state at selected target genes [17], including the loss
of 5hmC at a set of CpG island (CGI) promoters [23].
Furthermore, 5hmC patterns are dramatically altered
in several human cancer types includingHCC [23,24].
Thus, 5hmC profiles may be useful as a biomarker of
both normal and abnormal liver physiology. Here we
perform the first genome-wide analysis of liver 5hmC
patterns in a mouse model of diet-induced obesity
(DIO) and find that hepatic steatosis associates with
reversible 5hmC changes at a discrete number of
functionally important genes.
Results
DIO associates with hepatic steatosis and altered
transcription of functionally relevant genes
To explore the effects of diet-induced obesity on
hepatic 5hmC we used a well-characterised mouse
model of diet-induced obesity [25]. Maintaining
adult male C57BL/6 mice on HFD or CON diets
resulted in increased weight gain (Figure 1(a)) and
increased fat pad weight (Supplementary Figure 1A),
fasting hyperglycaemia, glucose intolerance
(Supplementary Figure 1B) and insulin resistance
(Supplementary Figure 1C). There were no differ-
ences in liver weight when corrected to total body
weight, however HFD did induce hepatic periportal
macrovesicular steatosis and a higher NAS steatosis
score (Figure 1(b) and Supplementary Figure 2). No
lobular necroinflammation or hepatocellular bal-
looning, the other features included in the NAS
system, were present in the liver of any mouse in
the study such that total NAS and the NAS steatosis
score were always identical. As expected, given the
lack of inflammation or ballooning to indicate stea-
tohepatitis, there was no fibrosis in any mouse. We
performed global hepatic transcriptome microarray
analysis on CON (n = 4) and HFD (n = 8) mice.
Analysis of the top 200 varying transcripts onmicro-
array was sufficient to cluster individuals by
Euclidean distance with minimal variance between
individuals in each group (Supplementary Figure 3).
At a threshold of 10% change with an adjusted
p-value of 0.05, 154 genes were upregulated and
204 downregulated (Figure 1(c)). Such transcrip-
tional derangement is comparable with human
NAFLD datasets [9,26]. These included functionally
relevant genes; the most enriched upregulated path-
way was cholesterol biosynthesis GO:0006695
(adjusted P-value 8.2 × 10−12), with 12 of 154 genes
directly involved in this process. Differential candi-
date gene expression was confirmed by qPCR
(Figure 1(d)).
Weight loss results in improvements in the clinical
picture of NAFLD and studies report resolution of
NASH-associated changes in DNA methylation fol-
lowing bariatric surgery [9]. To examine any reversi-
bility, 17-week HFD animals were switched to CON
for 12 weeks (HFD-reversal) whilst controls were
maintained on CON (control-reversal). HFD-
reversal prompted rapid weight loss (Figure 1(a)),
normalization of fat pads (Supplementary Figure
1A), glucose/insulin concentrations (Supplementary
Figure 1B and C) and reduced hepatic steatosis
(Figure 1(b) and Supplementary Figure 2) assessed
by NAS steatosis scoring. Weight loss also resulted in
almost complete resolution of gene expression
changes (Figure 1(d)).
Liver 5hmC profiling of control and HFD mice
Having established a model reflecting the metabolic
and histological characteristics of NAFLD we pro-
ceeded to quantify total 5hmC by Liquid
Chromatography–Mass Spectrometry (LC-MS).
HFD was not associated with changes in global
5hmC levels (Figure 2(a)). To examine genome-wide
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5hmC changes and investigate any discrete associa-
tions with transcriptional state, we undertook hydro-
xymethyl-DNA immunoprecipitation followed by
semi-conductor sequencing (hMeDIP-seq) in CON
(n = 2) and HFD (n = 4) liver. As previously reported
[16,27], relative 5hmCenrichmentwas present in gene
c
ba
d
Figure 1. HFD associates with reversible hepatic steatosis and transcriptional derangement. (a) HFD induces weight gain. Data analysed
by repeated measures two-way ANOVA with Tukey post hoc testing for multiple comparisons **p < 0.01 for HFD versus CON. (b) HFD was
associated with an increase in hepatic steatosis score, assessed through the application of the NAS system. Data analysed by Kruskal Wallis
test with Dunn’s post hoc test for multiple comparisons **p < 0.01 for HFD versus CON. (c) Volcano plot of CON and HFD liver showing up-
(red) and downregulated (blue) transcripts (adjusted p < 0.05 (Benjamini-Hochberg) and change >10%). (d) qPCR of cholesterol synthesis
mediators in CON, HFD, HFD-reversal and CON-reversal (n = 10/group) *p < 0.05, **p < 0.01 versus CON.
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bodies and liver enhancer regions with lesser enrich-
ment in promoters and minimal reads across tran-
scriptional start sites (TSS) and intragenic regions
(Figure 2(b)). Inter-individual 5hmC profiles were
highly consistent (Figure 2(c,d)). Linear regression
analysis comparing transcriptional and 5hmCchanges
revealed a highly significant relationship at gene
bodies (Figure 3(a)), but not promoters, enhancers
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Figure 2. 5hmC profiles are highly reproducible and HFD and weight loss do not associate with global 5hmC changes. (a) LC-MS
analysis of hepatic 5hmC in CON and HFD mice. (b) Schematic representation of gene regions in relation to TSS. *p < 0.001 versus
intergenic regions (Wilcox rank sum test). (c) Integrated genome viewer outputs of hMeDIP-seq experiments visualising 5hmC
profiles over three constitutively active hepatic genes showing reproducibility between animals. Each histogram bar represents score
over one 150 bp window. (d) Sliding window analysis of 5hmC profile over all genes in CON (blue n = 2) and HFD (red n = 4) mice.
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orTSS (Supplementary Figure 4). Although analysis of
global 5hmC patterns did not differentiate CON from
HFD (Figure 3(b)i), further analysis indicated genic
5hmC gain over a discrete number of HFD-induced
(Figure 3(b)ii) and genic 5hmC loss at a separate dis-
tinct number of HFD-suppressed genes (Figure 3(b)
iii) enabling clear stratification between control and
HFD animals. 5hmC changes over functionally
Figure 3. HFD associates with reversible genic 5hmC enrichment at discrete genes with biological relevance. (a) Scatter plot of
changes in genic 5hmC versus transcriptional change; Δ5hmC = difference in mean number of normalised reads/150bp window. (b)
Z-score heatmap analysis with hierarchical clustering based on average gene body 5hmC for (i) all genes (ii) top 10 induced and (iii)
top 10 suppressed genes. (c) hmeDIP-qPCR validation of differentially hydroxymethylated loci and resolution in HFD-reversal group.
Data are fold change versus CON analysed by one way Anova with Tukeys test for multiple comparisons * = p < 0.05.
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relevant transcripts were validated by hMeDiP-qPCR
(Figure 3(c)).Weight loss resulted in reversal of 5hmC
changes to control baseline (Figure 3(c)).
Discussion
Observational human studies examining global DNA
methylation dynamics across the NAFLD spectrum
from hepatic steatosis to advanced NASH have
shown aberrant 5mC patterns over both gene body
and promoter regions of theoretically causative genes
with an inverse correlation with gene expression and
at least partial reversibility following bariatric surgery
and resolution of liver injury [8,9,28]. Further evi-
dence in support of a role for DNA methylation in
NAFLD comes from studies in mice showing that
dietary restriction ofmethyl donors or impairment of
methyl donor metabolism causes liver injury similar
to NAFLD [29,30] and dietary methyl donor supple-
mentation appears to protect rodents from high fat/
sucrose diet-induced hepatic steatosis [12]. However,
since conventional bisulphite sequencing methods
do not discriminate between 5mC and 5hmC
[20,21], any role for 5hmC in the pathogenesis and
progression of NAFLD is as yet uncharacterised.
Using a genome-wide analysis of liver 5hmC in
a mouse model of DIO we show that that hepatic
steatosis associates with reversible 5hmC changes at
a discrete number of functionally important genes.
Diet-induced hepatic steatosis is associated with
altered expression of genes that play a role in NAFLD
pathogenesis, in association with altered 5hmC pro-
files.We have previously shown that short- and long-
term exposure to the non-genotoxic carcinogen phe-
nobarbital leads to dynamic changes in the liver
5-hydroxymethylome [17,23]. Here we extend this
work to show that disease-associated ‘environmental’
insults such as DIO can drive subtle changes in
hepatic 5hmC, which may potentially be magnified
in animals that progress to NASH and subsequent
HCC [23]. Although there were no global differences
in 5hmC, changes in 5hmCwere identified at specific
genes known to play a role in NAFLD pathogenesis,
with 5hmC gain over a discrete number of HFD-
induced genes and 5hmC loss at HFD-suppressed
genes. This is consistent with human studies which
show that 5hmC is enriched in genes with intermedi-
ate/high expression, and is overrepresented in genes
involved in active metabolic and catabolic processes
[16]. Additionally, the data are consistent with our
previous studies using phenobarbital which show
that 5hmC patterns are perturbed over a set of
genes that are induced on phenobarbital exposure
and that these are largely reproducible across multi-
ple liver samples [17]. The observed alterations in the
expression of genes that play a role in NAFLD patho-
genesis, along with their altered 5hmC profiles are
largely reversible with weight loss. This supports data
from human studies reporting resolution of NASH-
associated changes in DNAmethylation with weight
loss following bariatric surgery [9], and in mouse
liver following drug exposure [14].
The progression from NAFLD, through NASH,
fibrosis and cirrhosis is highly variable between indi-
viduals and is influenced by genes and environmen-
tal factors, with only a minority of individuals
reaching end-stage liver disease and/or developing
HCC [31]. This, coupled with a lack of understand-
ing of the precise mechanisms underpinning the
progression of NAFLD, makes prognosis and patient
stratification difficult and has limited the develop-
ment of reliable biomarkers of risk and effective
therapeutic interventions. Recent work in mice and
humans has identified methylation of the genic
region of Igfbp2 as a ‘risk epigenotype’ in NAFLD
and NASH [9,32]. In mice susceptible to the devel-
opment of diet-induced obesity, Igfbp2 is hyper-
methylated and transcriptionally suppressed prior
to the development of hepatic steatosis and this is
stable over time [32]. Obese humans with glucose
intolerance have increased DNA methylation at
IGFBP2 in peripheral blood cells [32], and the
IGFBP2 locus is hypermethylated in association
with decreased expression in liver biopsy specimens
from individuals with NASH [9]. Finally, overex-
pression of Igfbp2 reverses diabetes and steatosis in
obese mice [33]. Our finding that DIO associates
with decreased Igfbp2 expression (Figure 1(d)) and
5hmC loss (Figure 3(b)iii) builds on these data and
supports the utility of this model for NAFLD studies.
Additional studies are required to determine the
extent to which the 5hmC changes are functionally
important or simply reflect changes in gene
expression and whether they are a consequence
rather than a cause of the disease. Importantly,
these changes may be confounded by differences
in cell composition in disease states. Nevertheless,
our study has implications for the development of
6 M. J. LYALL ET AL.
biomarkers, and further studies of 5hmC
dynamics, for example, in in vitro models [34,35]
and in humans will provide an exciting strategy to
follow the molecular events associated with the
progression of NAFLD and HCC. In terms of
clinical utility, given the invasive nature of liver
biopsies developing biomarkers in cell-free DNA
(cfDNA) would be of clear benefit. Recent studies
have shown the potential utility of 5mC analysis in
circulating cell-free cfDNA in the stratification of
liver disease subtypes [36] and the expansion of
these studies to include 5hmC profiling may pro-
vide additional information, since for example,
tumour-specific changes in 5hmC in cfDNA are
detectable in a range of cancers including HCC
[37]. Understanding the mechanisms underlying
the changes in 5hmC and how 5hmC profiles
relate to disease progression may additionally
lead to the development of novel therapeutics to
manage liver disease [38]. In conclusion, we pro-
pose that 5hmC profiles are a useful signature of
gene transcription and a marker of cell state in
NAFLD and suggest that 5hmC profiles hold
potential as a biomarker of abnormal liver physiol-
ogy in association with obesity and beyond.
Materials and methods
Animal care and husbandry
All experiments were carried out under a UK Home
Office licence in accordance with the British Home
Office Animals (Scientific Procedures) Act 1986, fol-
lowingARRIVEguidelines andwith institutional ethi-
cal committee approval. For all experiments, a 12-h
light cycle (07.00 h to 19.00 h) and 12-h dark cycle was
implemented throughout and the temperature was
maintained at 22°C ± 2°C. Adult C57BL/6J males
(Charles River) were maintained under controlled
conditions in social groups of five animals per cage.
Mice were maintained on control (CON, 11% kcal
from fat; D12328, Research Diets) or a high-fat diet
(HFD, 58% kcal from fat; D12331 Research Diets) for
17 weeks to induce obesity (n = 10/group). Glucose
tolerance tests were performed at 17 weeks. After this,
mice were killed at 17 weeks and liver and fat pads
dissected, weighted and snap frozen on dry ice. To
identify whether any changes were reversible with
weight loss, we performed a second experiment in
a further cohort of mice. In this ‘reversal’ experiment,
a cohort of adult male C57BL/6J mice wasmaintained
on identical diets (control diet D12328 or HFD
D12331; n = 10/group) for 17 weeks. After 17 weeks,
the control group was maintained on diet D12328
(control-reversal) whilst mice on the HFD were
switched to the control diet (HFD-reversal). Both
groups remained on the control diet for a further 12
weeks. Glucose tolerance tests were performed at 28
weeks. ‘Reversal’ group mice were killed at 29 weeks
and liver and fat pads dissected, weighted and snap
frozen on dry ice. A schematic diagram describing the
experiment is presented in Supplementary Figure 5.
Phenotyping
Mice were fasted for 6 h prior to intraperitoneal
injection with 2 g glucose/kg body weight of 40%
w/v solution D-glucose (Sigma). Blood glucose
concentrations were quantified using
a glucometer (One Touch Ultra, Roche). Insulin
concentrations were measured using the Mercodia
Ultrasensitive Mouse Insulin ELISA kit
(Mercodia). HOMA-IR was calculated using the
formula HOMA-IR = (fasting plasma insulin
x fasting plasma glucose)/22.5 [39].
For histology, liver sections were fixed in formalin
10% solution for 24 h, transferred to 100% ethanol and
mounted in paraffin blocks prior to staining with
haematoxylin and eosin or picosirius red. Stained sec-
tions were independently assessed by a consultant
transplant liver histopathologist from the national
liver transplant centre, experienced in evaluation of
histology in clinical trials and translational models of
NAFLD. TheNAFLD activity score (NAS) [40] can be
used to quantify features ofNAFLD in human disease.
The same features can be evaluated in rodent models
of NAFLD, as previously described [41]. Features of
steatotic injury were scored on a scale from 0 to 8
(steatosis 0–3, lobular inflammation 0–3 and hepato-
cyte ballooning 0–2) on H&E stained sections.
Fibrosis was assessed from the PSR-stained sections
by applying the fibrosis score used withNAS. Analysis
was undertaken blinded to all other data.
Transcriptome profiling
mRNA was extracted from snap frozen liver tissue
and ‘on column’ DNase-treated using Qiazol,
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DNaseI and an RNeasy kit (Qiagen). 500 ng
mRNA from CON (n = 4) and HFD (n = 8)
were biotin labelled (Illumina TotalPrep, Life
Technologies) and hybridised to Illumina Mouse
WG-6 Arrays at the Wellcome Trust Clinical
Research Facility Genetics Core, Western General
Hospital, Edinburgh, UK. Intensity data were gen-
erated using a HiScan array scanner (Illumina)
and analysed using iScan Illumina software. Raw
data were uploaded to R version 3.12 (www.r-pro
ject.org). Quality control, background subtraction,
stabilization of variance and RSN normalization
were performed using the Lumi Package.
Application of Bayesian statistical methods and
differential expression with Benjamini-Hochberg
adjustment for multiple comparisons was per-
formed using the Limma Package (both packages
from bioconductor (http://creativecommons.org/
licenses/by/4.0/www.bioconductor.org). Plots
were generated using Base R, Heatmap.2 (gplots
package) or ggplot2. Unsupervised clustering was
performed using Euclidean distance. For valida-
tion, mRNA was reverse transcribed using the
High Capacity cDNA Reverse Transcriptase Kit
(Life Technologies). Quantitative real-time PCR
validation was performed using Roche Universal
Probe Library (Roche) or Taqman PCR assays
(Life Technologies) on the Roche Lightcycler 480
(Roche). Gene expression is presented relative to
the mean of two housekeeping genes as indicated.
Primers are listed in Supplementary Table 1.
Global quantification of 5hmC using liquid
chromatography–mass spectrometry
DNA extraction was performed using the Qiagen
DNeasy Blood and Tissue Kit (Qiagen) and RNase
treated with RNase A (Purelink, Ambion). Global
quantification of 5hmC was performed using Liquid
Chromatography–Mass Spectrometry (LC-MS).
Nucleotide monophosphates were separated on 150
× 4.6 mm SeQuant ZIC-pHILIC column (Millipore
(UK) Ltd) using a BioRS 3000 (ThermoFisher
Scientific), with a gradient 90% to 5% B in 10 min,
where B = acetonitrile and A = 20mM ammonium
carbonate. Ions were analysed in negative mode
using a Q-Exactive (ThermoFisher Scientific) with
scan range 300–350 m/z and resolution 70k.
Hydroxymethylcytosine DNA
immunoprecipitation (hMeDIP)
DNA extraction was performed using the Qiagen
DNeasy Blood and Tissue Kit (Qiagen) and RNase
treated with RNase A (Purelink, Ambion). 20 μg
genomic DNA was sonicated using a Bioruptor to
fragments between 100 and 600 base pairs (mean
250–300 base pairs). 2.5 μg of sonicated DNA was
diluted to 450 μl in TE buffer and denatured for 10
min at 90°C in a heat block before cooling for 5
min at 4°C and diluting to a final volume of 500 μl
immunoprecipitation buffer (10 mM sodium
phosphate (pH 7.0), 140 mM NaCl, 0.05% Triton
X-100). Ten percent input was removed at this
stage. One microliter of anti-5hmC antibody
(Active Motif) antibody was then added to the
remaining sample and incubated for 3 h at 4°C.
40 μl of Dynabeads protein G (Invitrogen) was
prewashed with BSA 0.1% in PBS and added to
the DNA/antibody mixture for 1 h at 4°C. Beads
were then collected by magnetic rack, washed
three times with 1 ml of cold IP buffer, re-
suspended in 250 μl of digestion buffer (50 mM
Tris-HCl pH 8.0, 10 mM EDTA pH 8.0, 0.5% SDS)
and treated with 20 μl of proteinase K 20 mg/ml
(Roche) in a thermoshaker at 1000 rpm, 55°C
overnight. Beads were then removed using
a magnetic rack and the enriched fraction and
input samples were then purified using the
Qiagen Qiaquik PCR Purification Kit (Qiagen)
with elution in 22 μl of water. Adequate enrich-
ment was determined using negative (β-actin and
Gapdh promoter) and positive control regions
(Tex19.1 promoter and H19 intragenic) as indi-
cated in the primer list. 1:10 dilution was used for
qPCR analysis. For semiconductor sequencing, 10
μl was amplified for 18 cycles using a SeqPlex
DNA Amplification Kit (Sigma).
100 ng of DNAwas used to generate a DNA library
from each sample using the Ion Xpress Plus Fragment
Library Kit (Thermo Fisher Scientific). During this
process, DNA fragments were end repaired and
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ligated to specific barcode adaptors before being
amplified (eight cycles) and twice purified using the
Agencourt AMPure XP PCR Clean Up Kit (Beckman
Coulter). Libraries were quality controlled using the
Agilent Bioanalyser DNA HS Kit (Agilent) and
pooled in equimolar pairs prior to template prepara-
tion using the Ion PI™ Hi-Q™ OT2 200 Kit (Thermo
Fisher Scientific) and sequencing on the Ion Torrent
semiconductor sequencer using the Ion PI™ Hi-Q™
Sequencing Kit (Thermo Fisher Scientific) and an
Ion PI™ Chip Kit v3 (Thermo Fisher Scientific). For
consistency, each sample was sequenced on a PI chip
with its own input. Each sample was sequenced to
a depth of ~30 million reads prior to quality control.
Raw sequencing data were quality controlled, filtered
and aligned using Ion Torrent suite software (Life
Technologies) and then normalised to total reads in
R using bespoke scripts. Relative 5hmC levels per 150
bp window were determined using the ‘sliding win-
dows’ function on the Galaxy server at IGMM,
Western General Hospital, UK. Genomic annotation
data for mouse (mm9 build) analyses were down-
loaded from the University of California Santa Cruz
Genome Bioinformatics Resource. Genomic co-
coordinates of transcriptional start sites and stop
sites were identified from the mm9 build of the
mouse genome and downloaded from the University
of California Santa Cruz research facility website
(https://genome.ucsc.edu/). Promoter regions were
defined as the region 1kb upstream of the TSS.
Enhancer region co-ordinates were predicted by
a chromatic signature of the presence of H3K4me1
but absence of H3K4me3 histone modifications and
were downloaded from the mouse ENCODE project
(http://chromosome.sdsc.edu/).
Statistics
Prism GraphPad software (GraphPad Software Inc.)
was used for statistical analysis of animal phenotype
data. Data were routinely analysed for normality and
outliers and non-parametric tests used where
required. Data are shown as mean ± SEM.
Data availability
Sequencing data have been uploaded to the Gene
Expression Omnibus (GSE109138).
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